Seven Corners Initiates Coverage on Allergan (AGN) With A Sell, Due to Non-GAAP Accounting Concerns

January 20, 2017


Today Seven Corners Capital Management initiated coverage on Allergan (AGN). Specifically, we are short AGN for, among other things, the following reasons: (1) Last year the SEC issued guidance on impermissible non-GAAP financial metrics; (2) Allergan's "non-GAAP EPS" measure appears to violate these rules; and (3) Allergan will likely need to cease using (or substantial alter) its "non-GAAP EPS" metric. Due to the belief that AGN's true "economic earnings" are well below its "non-GAAP EPS" numbers and guidance, we view AGN as substantially overvalued currently.


To find a PDF containing our full AGN writeup, please visit our Research section (link here).

Please reload

Featured Posts

SCC Q1 2020 Portfolio Update

May 31, 2020

Please reload

Recent Posts
Please reload

Please reload

50 Vanderbilt Ave, 4th Fl, New York, New York 10017

Content © 2016 Seven Corners Capital Management, LLC. All rights reserved.

  • LinkedIn Social Icon
  • RSS Social Icon
  • Twitter Social Icon
  • SA
  • Image by sporlab